Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML

NCT01957644 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic

Interventions

DRUG: Azacitidine
DRUG: Volasertib

Sponsor

Boehringer Ingelheim